PF-06928215 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a targeted therapy for specific types of cancer, particularly those driven by certain genetic mutations or signaling pathways. The compound is designed to inhibit key proteins or enzymes involved in tumor growth and progression, potentially slowing down or halting cancer cell proliferation. Researchers are exploring its efficacy in preclinical and clinical trials to determine its safety, dosage, and effectiveness in treating malignancies. Additionally, PF-06928215 may be used in combination with other cancer therapies to enhance treatment outcomes and reduce resistance to existing drugs. Its development represents a promising approach to personalized medicine in cancer treatment.